S. Brown

发表

Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours

D. Shaw, L. Weiner, A. Mazar, 2006, British Journal of Cancer.

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.

M. Carducci, L. Siu, A. Kalita, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors

G. Pond, A. Oza, L. Siu, 2006, Anti-cancer drugs.

Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.

D. Hayes, G. Pond, J. Dancey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and / or erbB 2 Expressing Adenoid Cystic Carcinoma and Non – Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

D. Hayes, G. Pond, J. Dancey, 2007 .

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.

E. Lamont, G. Pond, E. Vokes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.

G. Pond, A. Oza, M. Carey, 2007, Gynecologic oncology.

142 Phase II study of imatinib mesylate in salivary gland adenoid cystic carcinoma

E. Lamont, L. Siu, A. Murgo, 2003 .

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

G. Pond, A. Oza, J. Dancey, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.